Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-03-11
DOI
https://doi.org/10.1186/s12885-025-13648-5
Citations
8
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
10.58

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell

Michihisa Moriguchi, Kaoru Tsuchiya, Masafumi Ikeda, Yozo Sato et al.
8 citations
BMC Cancer
Hepatocellular Carcinoma Treatment and Prognosis
10.58
article

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocell

Michihisa Moriguchi, Kaoru Tsuchiya, Masafumi Ikeda, Yozo Sato, Teiji Kuzuya, Tetsutaro Hamano, Koichiro Yamakado, Tetsuo Takehara, Yoshitaka Inaba, Takahiro Kodama, Toshifumi Tada, Miyuki Sone, Yoshihisa Kodama, Hideki Iwamoto, Tatsuya Yamashita, Sadahisa Ogasawara, Hideyuki Nishiofuku, Masatoshi Kudo, Makoto Ueno, Kazuomi Ueshima
article en
8 citations

Abstract

No abstract available for this paper.
BMC CancerVol. 25(1)
Kurume University (JP), Chiba University (JP), Kanagawa Prefectural Hospital Organization (JP), Kyoto Prefectural University of Medicine (JP), Kanazawa University Hospital (JP), Fujita Health University Hospital (JP), Himeji Red Cross Hospital (JP), Aichi Cancer Center (JP), Teine Keijinkai Hospital (JP), National Cancer Center Hospital East (JP), Musashino Red Cross Hospital (JP), Kanagawa Cancer Center, Nara Medical University (JP), Hyogo University (JP), Kindai University (JP), The University of Osaka (JP)
Chugai Pharmaceutical
Good health and well-being
Openalex Percentile: Top 1%
Hepatocellular Carcinoma Treatment and Prognosis
10.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.